Search Results for "RNAi"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B

Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-term Lumasiran

Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life

Annualized attack rate reductions vs historical data and hemin use of patients with acute hepatic porphyria in phase 3 ENVISION trial who were not attack-free after 6 months of givosiran treatment

Long-Term Lumasiran Treatment, Kidney Function, and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1

Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment

Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension

Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria

Kidney Function, Isolated Kidney Transplant, and Health-Related Quality-of-Life Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-Term Lumasiran

Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria: 36-Month Results of the Phase 3 ENVISION Randomized Clinical Trial

TRITON-CM: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

GRAPHICAL ABSTRACT: KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Patient demographics and clinical characteristics at enrolment in ELEVATE, an international registry of acute hepatic porphyria

GRAPHICAL ABSTRACT: Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN

This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Zilebesiran as Add-On Therapy in Patients With Hypertension Who Have Cardiovascular Disease or are at High Cardiovascular Risk: The ZENITH Trial Design

Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

Home Blood Pressure Reductions with Zilebesiran in Patients with Mild-To-Moderate Hypertension are Consistent with Ambulatory and Office Blood Pressure Reductions in the KARDIA-1 Study

Vutrisiran Reduces Days Lost to Death andor Hospitalization Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Comparison of Patients With Primary Hyperoxaluria 1 and Late-Stage Chronic Kidney Disease From BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial

KARDIA-3: zilebesiran as add-on therapy in adults with hypertension who have established cardiovascular disease or are at high cardiovascular risk

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "RNAi"

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN

This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.